In terms of molecular alterations, high-grade serous carcinoma is usually associated with BRCA1 or BRCA2 germline mutations and TP53 somatic mutations, which are identified in 96% of the tumor samples [15]. This evidence concerns the gene TP53 and serous adenocarcinoma.